000			02257cam a22003617 4500
001			w22745
003			NBER
005			20211020105124.0
006			m o d
007			cr cnu||||||||
008			210910s2016 mau fo 000 0 eng d
100	1		_aDafny, Leemore.
245	1	0	_aWhen Discounts Raise Costs: _bThe Effect of Copay Coupons on Generic Utilization / _cLeemore Dafny, Christopher Ody, Matthew Schmitt.
260			_aCambridge, Mass. _bNational Bureau of Economic Research _c2016.
300			_a1 online resource: _billustrations (black and white);
490	1		_aNBER working paper series _vno. w22745
500			_aOctober 2016.
520	3		_aBranded pharmaceutical manufacturers frequently offer "copay coupons'" that insulate consumers from cost-sharing, thereby undermining insurers' ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. To overcome endogeneity concerns, we exploit cross-state and cross-consumer variation in coupon legality. We find that coupons increase branded sales by 60+ percent, entirely by reducing the sales of bioequivalent generics. During the five years following generic entry, we estimate that coupons increase total spending by $30 to $120 million per drug, or $700 million to $2.7 billion for our sample alone.
530			_aHardcopy version available to institutional subscribers
538			_aSystem requirements: Adobe [Acrobat] Reader required for PDF files.
538			_aMode of access: World Wide Web.
588	0		_aPrint version record
690		7	_aI11 - Analysis of Health Care Markets _2Journal of Economic Literature class.
690		7	_aL40 - General _2Journal of Economic Literature class.
690		7	_aL65 - Chemicals • Rubber • Drugs • Biotechnology • Plastics _2Journal of Economic Literature class.
700	1		_aOdy, Christopher.
700	1		_aSchmitt, Matthew.
710	2		_aNational Bureau of Economic Research.
830		0	_aWorking Paper Series (National Bureau of Economic Research) _vno. w22745.
856	4	0	_uhttps://www.nber.org/papers/w22745
856			_yAcceso en línea al DOI _uhttp://dx.doi.org/10.3386/w22745
942			_2ddc _cW-PAPER
999			_c325377 _d283939